Sarepta Therapeutics (SRPT) Change in Receivables (2010 - 2026)

Sarepta Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 105.95% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$264.6 million (down 194.29% YoY), while the FY2025 annual figure was -$203.8 million, down 201.04% from the prior year.
• Change in Receivables for Q1 2026 stood at -$3.4 million, down from $2.5 million in the prior quarter.
• The five-year high for Change in Receivables was $167.5 million in Q4 2024, with the low at -$132.1 million in Q2 2025.
• The 5-year median for Change in Receivables is $13.0 million (2023), against an average of $14.2 million.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables soared 3598.81% in 2023, then sank 602.2% in 2025.
• Sarepta Therapeutics' Change in Receivables stood at $13.1 million in 2022, then jumped by 521.02% to $81.5 million in 2023, then soared by 105.55% to $167.5 million in 2024, then plunged by 98.51% to $2.5 million in 2025, then plunged by 236.97% to -$3.4 million in 2026.
• Business Quant data shows SRPT's Change in Receivables at -$3.4 million in Q1 2026, $2.5 million in Q4 2025, and -$131.6 million in Q3 2025.